

**Editor's Comment:**

After a detailed review of your paper focusing on VPA (Valproic Acid) and its commercial formulation, Depakote, I have a few critical points to address:

**Classification of VPA:** In your paper, there appears to be a misrepresentation of Valproic Acid (VPA). While VPA, especially in its Depakote formulation, is a renowned anticonvulsant and mood stabilizer primarily used for treating conditions like epilepsy and bipolar disorder, it is not traditionally classified as an antidepressant. Ensuring clarity on this distinction is essential to prevent potential misconceptions.

**Conclusion Analysis:** The potential confusion about VPA's classification might have influenced the conclusions drawn in the paper. It's crucial for the conclusion to reflect an accurate interpretation of the drug, based on established and reputable literature.

**Urgent Revision Recommended:** Given the noted discrepancies, I advise a rigorous revision of the sections detailing VPA's properties and applications. Accurate representation is vital for upholding the publication's credibility and educating its audience correctly.

Your dedication to research is commendable, and with the proposed corrections, your paper can significantly contribute to our scientific repository. After implementing the revisions, kindly resubmit the manuscript for another round of review.

**Editor's Details:**

Dr. Shahana Ayub  
Staff Psychiatrist, Cornerstone Family Healthcare, Newburgh, NY 12550, USA.